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Human erythropoiesis serves as a paradigm of phys-
iologic cellular differentiation. This process is also
of considerable interest for better understanding
anemias and identifying new therapies. Here, we
apply deep transcriptomic and accessible chromatin
profiling to characterize a faithful ex vivo human
erythroid differentiation system from hematopoietic
stem and progenitor cells. We reveal stage-specific
transcriptional statesandchromatinaccessibilitydur-
ing various stages of erythropoiesis, including 14,260
differentially expressed genes and 63,659 variably
accessible chromatin peaks. Our analysis suggests
differentiation stage-predominant roles for specific
master regulators, including GATA1 and KLF1. We
integrate chromatin profiles with common and rare
genetic variants associated with erythroid cell traits
anddiseases, finding that variants regulatingdifferent
erythroid phenotypes likely act at variable points dur-
ing differentiation. In addition, we identify a regulator
of terminal erythropoiesis,TMCC2,morebroadly illus-
trating the value of this comprehensive analysis to
improve our understanding of erythropoiesis in health
and disease.
INTRODUCTION
Erythropoiesis describes the process of proliferation and differ-
entiation of hematopoietic stem and progenitor cells (HSPCs)3228 Cell Reports 27, 3228–3240, June 11, 2019 ª 2019 The Author(
This is an open access article under the CC BY-NC-ND license (http://through distinct functionally and morphologically defined stages
to produce enucleate reticulocytes. In the circulation, these cells
mature further into red blood cells (RBCs), which are the key
transporters of oxygen and carbon dioxide for cellular respiration
(Nandakumar et al., 2016; Sankaran and Weiss, 2015). In adult
humans, approximately 2 million RBCs are produced every
second in the bone marrow through the tightly coordinated
process of erythropoiesis, making RBCs the most abundant
cell type in the human body (Palis, 2014). Congenital as well as
acquired defects may lead to various forms of anemia, the lack
of sufficient RBCs, causing significant morbidity and mortality
(Sankaran and Weiss, 2015).
Genetic and cell biological approaches have provided impor-
tant insights into normal RBC differentiation and how this
process is perturbed in different blood diseases, such as ane-
mias (Arlet et al., 2014; Giani et al., 2016; Khajuria et al., 2018;
Ludwig et al., 2014, 2016). Our knowledge of this process has
been further enhanced by comprehensive transcriptomic and
proteomic profiling of distinct stages of neonatal and adult
erythropoiesis (An et al., 2014; Gautier et al., 2016; Li et al.,
2014; Yan et al., 2018). Additional efforts have recorded the
accessible chromatin landscape (Buenrostro et al., 2018; Cor-
ces et al., 2016) and epigenetic marks such as histone modifica-
tions (Huang et al., 2016) at select stages and investigated the
role of genetic variation and chromatin accessibility in murine
cellular models (Behera et al., 2018). However, we lack a
detailed characterization of the accessible chromatin landscape
and transcription factor dynamics throughout the entire process
of human erythroid differentiation, even though such character-
ization would facilitate a more comprehensive understanding of
gene regulatory dynamics and their relation to human genetic
variation and disease.s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Here, we leverage the assay for transposase accessible chro-
matin using sequencing (ATAC-seq) (Corces et al., 2016, 2017)
to assess eight populations that chart the dynamic open chro-
matin landscapes of HSPCs undergoing the process of erythroid
differentiation. We integrate our data with matched deep
transcriptomic profiles, results from genome-wide association
studies (GWAS), and mutations resulting in human disease, to
facilitate a systems-level understanding of the molecular circuits
governing erythropoiesis in human health and disease. We show
that our chromatin accessibility profiles yield a detailed descrip-
tion of the regulatory elements and transcription factor dynamics
that control gene expression during human erythropoiesis. The
intersection with variants identified in GWAS and Mendelian dis-
eases reveal the differential and putative temporal contributions
of genetic variants in accessible chromatin in affecting human
erythroid traits and pathologies. Overall, our integrated analysis
framework provides a comprehensive resource to advance our
understanding of gene regulation and will expedite downstream
functional and validation studies of regulators, as exemplified by
our use of this dataset to identify a role for TMCC2 in terminal hu-
man erythropoiesis.
RESULTS
An Epigenomic and Transcriptional Time Course of
Human Erythroid Differentiation
To obtain a comprehensive and integrative picture of the chro-
matin and transcriptional landscape of human adult erythropoi-
esis, we differentiated CD34+ HSPCs from healthy donors
using an established three-phase erythroid differentiation pro-
tocol that allows the efficient production of mature enucleated
reticulocytes (Giani et al., 2016; Hu et al., 2013). We then
applied flow cytometry-activated cell sorting (FACS) using
well-characterized erythroid surface markers CD71, CD235a,
CD49d, and Band 3 (encoded by the SLC4A1 gene) across
multiple stages of the differentiation process to enrich for cells
at different stages of maturation (Hu et al., 2013), validated pu-
rity by morphology, and processed each population (P1–P8)
using ATAC-seq (FAST-ATAC) and RNA sequencing (RNA-
seq) (Smart-seq2) (Figures 1A, 1B, and S1A) (Corces et al.,
2016; Picelli et al., 2014). Each population was processed in
three or four replicates using cultured cells from two or three
healthy adult human donors, resulting in a total of 28 paired
RNA-seq and ATAC-seq libraries. Overall, our ATAC-seq li-
braries were sequenced to an average depth of 21.5 million
aligned reads/sample (mean 75.3 million/population), and the
RNA-seq libraries were sequenced to an average depth 26.1
million aligned reads/sample (mean 91.1 million/population)
(Tables S1 and S2).
Stage-Specific Chromatin Accessibility and
Transcriptional Variability in Human Erythropoiesis
To yield a complete accessible chromatin and transcriptional
trajectory during human erythroid differentiation, we included
published profiles of paired sequencing data from early hemato-
poietic stem and progenitor populations, including hematopoiet-
ic stem cells (HSCs), multipotential progenitors (MPPs), common
myeloid progenitors (CMPs), and megakaryocyte erythroid pro-genitors (MEP)s (Corces et al., 2016). Indeed, principal-compo-
nent analysis on our paired datasets shows a continuous trajec-
tory of erythroid differentiation and high concordance between
replicates (Figures 1C, 1D, S1B, and S1C). Population P1 was
most similar to myeloid progenitor cells (MyP) that did not
commit to the erythroid lineage in our in vitro culture but were
included in many downstream analyses. Population P2 was en-
riched for colony-forming unit-erythroid cells (CFU-E), P3 and P4
for proerythroblasts (ProE1 and ProE2), P5 for basophilic eryth-
roblasts (BasoE), P6 for polychromatic erythroblasts (PolyE), and
P7 for orthochromatic erythroblasts (OrthoE), which were further
enriched with reticulocytes in P8 (Orth/Ret), as confirmed by
morphology as well as comparison with published transcrip-
tional profiles (Yan et al., 2018) (Figures S1A and S2A), providing
an independent validation for this dataset of human erythroid
differentiation. Overall, chromatin accessibility profiles were of
high quality (Figure S1D) and across populations, we detected
63,659 variably accessible chromatin peaks and 14,260 differen-
tially expressed genes (Figures 1E and 1F). The majority of
identified peaks mapped to distal, intronic, and promoter gene
regions, with a comparable distribution with those in previous
reports profiling human T lymphocytes (Figures 1G and S1D)
(Qu et al., 2015).
Time-Dependent Modules of Transcriptional Regulation
Define Erythroid Differentiation Programs
To characterize transcriptional modules throughout human
erythroid differentiation, we used k-means clustering to identify
co-regulated genes. Using the gap statistic to determine an
appropriate number of clusters (Figure S2B), we identified seven
clusters of differentially expressed genes showing a wide range
of expression patterns and dynamics (Figure 2A; Table S3). From
the Z score-normalized gene expression values, we observed
population-specific expression primarily in presumed MyP
(cluster k3) and at the latest stages of erythroid differentiation
(OrthoE/Ret; cluster k7). Most other gene expression programs
were broadly expressed in early progenitor populations (clusters
k1 and k2) and throughout erythroid differentiation (clusters
k4–k6).
To determine the underlying cellular processes governed by
these patterns of expression variability, we performed Gene
Ontology (GO) analyses to identify biological processes that
were enriched within these clusters and that may be involved
in regulating erythroid differentiation (Figure 2B; Table S4).
RNA, non-coding RNA, and DNA processing-related gene
sets were most dominant during the earlier stages of terminal
erythroid differentiation (cluster k4). Cell cycle-related pro-
cesses showed maximum activity around the ProE1/2 stage
(cluster k5), consistent with the high proliferative capacity of
these cells. Heme biosynthetic and oxygen transport pro-
cesses showed highest activity at the BasoE and PolyE stage,
reflecting the peak of hemoglobin synthesis (cluster k6). Regu-
lation of catabolic processes dominate during the OrthoE/Ret
stage, as cellular organelles are being recycled before final
maturation into erythrocytes (cluster k7) (Figure 2B). Overall,
our transcriptional analysis revealed highly consistent findings
with those described in prior reports (An et al., 2014; Yan




Figure 1. An Epigenomic and Transcriptional Time Course of Human Erythroid Differentiation
(A) Schematic outline of generating matched transcriptome and open chromatin profiles across human erythropoiesis.
(B) FACS gating scheme showing expression of surface markers CD71, CD235a, CD49d, and BAND3 used to sort indicated populations P1–P8 (P1, MyP; P2,
CFU-E; P3, ProE1; P4, ProE1; P5, BasoE; P6, PolyE; P7, OrthoE; P8, Ortho/Ret).
(C and D) Principal-components plots of (C) RNA-seq data and (D) ATAC-seq data, colored by FACS-sorted populations. Color code indicated below.
(E) Number of chromatin accessibility peaks across populations. Error bars represent SEM number of peaks per population between replicates.
(F) Heatmap showing relative numbers of differentially accessible peaks (top, blue shades) and differentially expressed genes (bottom, red shade) between
populations.Dynamics of the Accessible Chromatin Landscape and
Enrichment of Transcriptional Regulatory Programs
Previous genome-wide analyses of accessible chromatin pro-
files have revealed a comprehensive repertoire of gene regulato-
ry elements, many of which appear to act in a cell type- and
tissue-specific manner (Thurman et al., 2012). However, we
have a limited understanding of the accessibility dynamics of
these elements during cellular differentiation. Our dense profiling
of erythroid populations at different stages of differentiation us-
ing ATAC-seq enables the most comprehensive description to
date of the dynamic accessible chromatin landscape throughout
human erythropoiesis (Figure 3A). Quantification of Tn5 insertion
density aroundCTCFmotifs as previously described (Buenrostro
et al., 2013) verified high-quality libraries throughout our differen-
tiation system (Figure S3A). Using k-means clustering and gap
statistic optimization (Figure S3B), we identify seven clusters
of differential accessible peaks, showing similar patterns and dy-
namics at key erythroid gene loci such as ALAS2 (Figure 3B),3230 Cell Reports 27, 3228–3240, June 11, 2019similar to what we describe for the transcriptomic profiles
described above (Figure 2A).
Cluster k1 contained regions of open chromatin showing
highest accessibility in HSPCs, which became less accessible
during early erythroid differentiation. By contrast, regulatory
elements in cluster k2 displayed slower closing dynamics
(decreasing accessibility). We also observed profound changes
from the ProE1/2 to the OrthoE stage. Some elements were
most accessible around the ProE1/2 stage but quickly closed
(lost accessibility) in BasoE (cluster k4), whereas cluster k5 con-
tained elements remaining accessible throughout the PolyE
stage. Interestingly, we also observed elements showing high-
est accessibility at the OrthoE stage immediately preceding
enucleation. This process has been typically associated with
increased nuclear condensation and an anticipated loss of
accessibility, also supported by an overall decreasing number
of accessibility peaks at late stages of differentiation (Figure 1E)
(Zhao et al., 2016). Of note, the late stage-specific peaks were
A B
Figure 2. Time-Dependent Modules of Tran-
scriptional Regulation Define Erythroid Dif-
ferentiation Programs
(A) Heatmap of all differentially expressed genes,
clustered by dynamic expression using k-means
clustering across hematopoietic progenitor pop-
ulations (HSC, MPP, CMP, and MEP) and stages of
erythropoiesis (MyP, CFU-E, ProE1, ProE2, BasoE,
PolyE, OrthoE, and Orth/Ret). Color bar, expression
Z score of differentially expressed genes.
(B) Top enriched Gene Ontology biological pro-
cesses for clusters K4, K5, K6, and K7 of differ-
entially expressed genes. The top five processes
are shown for each cluster and their log10(false
discovery rate [FDR]).enriched in genes displaying the highest levels of induction and
expression at the OrthoE stage, as exemplified by the TMCC2
locus, a gene highly induced in terminal erythropoiesis whose
role in this process has not been previously studied (Figures 6
and 7).
Our ATAC-seq dataset enables the use of chromVAR to infer
transcription factor (TF) variability and dynamics throughout
erythroid development (Schep et al., 2017). In brief, chromVAR
aggregates accessible regions sharing the same TF motif, then
compares the observed accessibility of all peaks containing that
TF motif with a background set of peaks normalizing for known
technical confounders. Among the most variably accessible
sequence motifs determined, we identified important hematopoi-
etic TF motifs such as from SPI1, GATA1, CEBPA, RUNX1, and
FOXD4 (Figures 3C and S3C). Notably, we observed profound
differences in the accessibility within our sampled populations,
including significant loss of inferred activity of erythroid master
regulator GATA1 after the BasoE stage (Figures 3D, S3D, and
4). Similar to regions of open chromatin most accessible at the
OrthoE stage (Figure 3A), we identified several TF motifs with
highest accessibility at this stage (FOSL1, NFE2, and FOXD4).
These findings suggest a possible role for these factors during
the most terminal stages of erythropoiesis and warrant further
investigation, noting that augmenting motif-based inference with
true-positive factor binding via chromatin immunoprecipitationCellsequencing (ChIP-seq) may enable greater
specification of individual factors. Overall,
our results provide comprehensive insights
into chromatin accessibility dynamics and
the distinct TF regulatory programs active
during human RBC development.
Regulatory Dynamics of Erythroid
Master Regulators during Terminal
Erythroid Differentiation
GATA1, TAL1, and KLF1 are master tran-
scriptional regulators of hematopoiesis
and are essential for erythroid develop-
ment (Arnaud et al., 2010; Ludwig et al.,
2014; Shivdasani et al., 1995). However,
their DNA binding and regulatory dynamics
in controlling gene expression in a stage-specific manner has not yet been fully resolved. Here, we inves-
tigated the relation between ATAC-seq Tn5 insertion density
(i.e., chromatin accessibility) and proximity to the canonical
GATA1-TAL1 and KLF1 motifs throughout erythroid differentia-
tion. Chromatin accessibility near canonical GATA1 motifs ap-
peared highest in BasoE, consistent with a peak in expression
of canonical GATA1 target genes at this stage as predicted using
gene set enrichment analysis (GSEA) (Figures 4A and 4B) (Lud-
wig et al., 2014; Subramanian et al., 2005). Interestingly,
GATA1 activity declined preceding enucleation, suggesting
that its expression becomes dispensable at the final stage of
erythroid differentiation. Indeed, using western blot analysis,
we documented reduced GATA1 protein levels in late-stage
erythroid cells in our in vitro culture system (Figures 4C, 4D,
S4A, and S4B), consistent with concomitant downregulation of
HSP70 protein levels and its protective role in caspase-3-depen-
dent GATA1 cleavage (Gautier et al., 2016; Ribeil et al., 2007)
(Figure S4C). In contrast, KLF1 motif accessibility and target
gene expression appeared to increase throughout terminal dif-
ferentiation, consistent with increasing transcript levels and
higher chromatin accessibility in the KLF1 locus throughout the
late stages compared with the GATA1 locus (Figures S4D–
S4G). These findings support the notion that GATA1 and KLF1
play distinct regulatory roles in orchestrating the erythroid matu-
ration program. As such, humanKLF1mutations result in distinctReports 27, 3228–3240, June 11, 2019 3231
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Figure 3. Dynamics of the Open Chromatin Landscape and Enrichment of Transcriptional Regulators
(A) Heatmap of all differentially accessible peaks, clustered using k-means clustering across hematopoietic progenitor populations (HSC, MPP, CMP, and MEP)
and stages of erythropoiesis (MyP, CFU-E, ProE1, ProE2, BasoE, PolyE, OrthoE, andOrth/Ret). Color bar, accessibilityZ score of differentially peaks identified by
ATAC-seq.
(B) Distribution of accessible peaks in the ALAS2 locus across sampled populations.
(C) Rank order plot of transcription factor binding sites with greatest variability in chromatin accessibility across sampled cell populations.
(D) Heatmap showing temporal changes in chromatin accessibility for the top 20 TFs with greatest accessibility variability between populations profiled. Color
bar, chromVAR accessibility deviation Z score.erythroid phenotypes (Arnaud et al., 2010; Borg et al., 2010)
compared with GATA1-associated pathologies; the latter are
characterized by altered erythroid lineage commitment or
impaired differentiation of erythroid progenitors (Campbell
et al., 2013; Crispino and Horwitz, 2017; Khajuria et al., 2018;
Ludwig et al., 2014; Sankaran et al., 2012a).
We next hypothesized that rare variants disrupting GATA1mo-
tifs would also be most accessible at stages of maximal GATA1
transcriptional activity. Investigating the chromatin accessibility
of 11 variants known to disrupt GATA1 regulatory elements,
including several in human Mendelian erythroid disorders (Cam-
pagna et al., 2014; Kaneko et al., 2014; Manco et al., 2000; Wa-
kabayashi et al., 2016), we indeed found that BasoE have
maximal chromatin accessibility in regulatory regions encom-
passing many of these variants (Figure 4E; Table S5). For
instance, GATA1 element mutations in uroporphyrinogen III syn-
thase (UROS), a heme biosynthetic enzyme implicated in
congenital erythropoietic porphyria (Solis et al., 2001), as well
as in the core promoter of the erythroid-specific RH50 antigen
(Iwamoto et al., 1998), both fell within chromatin peaks which
were maximally accessible in BasoE (Figures 4F and 4G). Alto-
gether, these findings emphasize the role of GATA1 in earlier
stages of human terminal erythroid differentiation.3232 Cell Reports 27, 3228–3240, June 11, 2019Human Genetic Variation in the Context of Chromatin
Dynamics
Motivated by our finding of differential GATA1 activity in rare
disease-associated erythroid variants, we next investigated
whether differential chromatin dynamics could extend more
broadly to common variants associated with RBC traits.
GWAS have identified thousands of common genetic variants
that fall within accessible regions of chromatin in diverse tissues
and cell types and have been associated with various human
phenotypes, including blood cell traits (Astle et al., 2016). How-
ever, it remains an open question as to how and at what stage of
differentiation or cell state these variants primarily affect he-
matopoietic development and traits. Given that the majority of
nominated genetic variants fall into gene-regulatory regions
and are thought to alter gene expression, we reasoned that
our comprehensive open chromatin profiles could provide in-
sights into the precise stages of erythroid development during
which such regulation may occur. First, we intersected hemato-
poietic cell type-specific regions of open chromatin with fine-
mapped variants affecting six commonly measured erythroid
cell traits nominated by a recent GWAS (Ulirsch et al., 2019).
Among the 114,905 individuals comprising this GWAS cohort,
4,327 (3.76%) had hemoglobin concentrations meeting the
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Figure 4. Regulatory Dynamics of Erythroid Master Regulators in Terminal Erythropoiesis
(A) ATAC-seq footprinting, showing that Tn5 insertion density near GATA1-TAL1motif is relatively lower inMyP andOrth/Ret comparedwith BasoE, whenGATA1
is most active.
(B) GATA1 transcriptional activity using GSEA edge statistics across indicated populations.
(C and D) Western blot showing decreasing GATA1 protein expression levels in differentiating primary human erythroid cells over time. FL, full-length protein
isoform of GATA1; S, short protein isoform of GATA1. Results of culture 1 (C) and culture 2 (D) are shown.
(E) Heatmap of chromatin accessibility intensity per population at loci at which rare variants disrupt GATA1 regulatory elements.
(F and G) Locus-specific examples of rare variants affecting GATA1motifs are shown in the promoters of (F) uroporphyrinogen III synthase and (G) RH50 antigen,
both demonstrating maximal chromatin accessibility in BasoE. Bar graphs indicate mean ± SEM log2 counts per million RNA-seq reads per population.criteria for clinical anemia as defined by the World Health Orga-
nization (2011), suggesting that our analysis may be relevant for
better understanding the genetics of both normal variation, as
well as disease risk. Overall, 347 of 1,789 (19.4%) fine-mapped
GWAS variants with posterior probability (PP) > 0.10 for causal
association fell within a chromatin-accessible region in one or
more of the characterized populations. Upon k-means clustering
of these variants by chromatin dynamics (Figures 5A and S5A;
Table S6), we observed that amajority showedmaximum acces-
sibility at specific stages of erythroid differentiation rather than
being uniformly accessible, suggesting potential windows of
active gene regulation.
We next sought to leverage this comprehensive data to more
finely assess the stages of erythropoiesis duringwhich RBC trait-
associated variants may act using g-chromVAR, a recently
developed high-resolution cell type enrichment tool (Ulirsch
et al., 2019). Interestingly, cells at the earlier stages of differenti-
ation (CFU-E and ProE1/2) were significantly enriched for
variants regulating hematocrit (HCT) and hemoglobin (HGB)
levels (Figure 5B). In contrast, the BasoE and PolyE stages
were significantly enriched for variants affecting mean corpus-
cular volume (MCV), mean corpuscular HGB (MCH), MCH con-centration (MCHC), and RBC count (Figure 5B). To dissect this
duality, we looked at high-confidence regulatory ATAC-seq
peaks containing fine-mapped variants with a combined PP of
0.10 or higher. Although fewer absolute variants were associated
with HGB and/or HCT relative to MCV, MCH, and/or RBC count,
the density of HGB and/or HCT variants in chromatin-accessible
regions was shifted toward earlier stages of erythropoiesis,
whereas a more balanced distribution was observed for MCV,
MCH, MCHC, and/or RBC count variants (Figures 5C, S5B,
and S5C). We note that HCT is calculated as the product of
RBC count and MCV, two traits that are negatively correlated,
such that when a variant alters the RBC count and MCV in
opposing directions, the net effect on HCT is neutralized. Indeed,
41% of fine-mapped variants associated with RBC count were
not associated with HGB or HCT (Figure S5D), consistent with
previous studies showing higher genetic correlations between
HGB and HCT compared with those with a RBC count (Ulirsch
et al., 2019). Thus, the enrichment for HGB and/or HCT variants
acting in earlier stages of erythropoiesis is likely driven in part by
HGB and/or HCT-associated variants affecting the RBC count
or MCV alone or in consistent directions, but not in opposite




Figure 5. Dynamic cis-Regulatory Variation across Stages of Erythropoiesis
(A) All ATAC-seq peaks containing fine-mapped (PP > 0.10) GWAS variants associated with red cell traits, clustered into nine groups. Color bar, chromatin
accessibility.
(B) g-chromVAR enrichments of six different red cell traits across stages of erythroid differentiation.
(C) Proportions of fine-mapped regulatory variants, grouped by trait, that are in more accessible chromatin in earlier versus later stages of erythropoiesis. An
early-accessible variant was defined as residing in an ATAC-seq peak with higher mean counts per million in the CFU-E, ProE1/2 populations relative to the
BasoE/PolyE populations, and a late-accessible variant was the opposite. (n) indicates the total number of fine-mapped (PP > 0.10) variants per trait.
(D–F) Representative examples of fine-mapped variants located within regions that have maximal chromatin accessibility in (D) late (BasoE-OrthoE), (E) early
(CFU-E, ProE1/2), or (F) both early- and late-stage erythroid populations. HGB, hemoglobin; HCT, hematocrit; MCH, mean corpuscular hemoglobin; MCHC,
mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RBC, red blood cell count. Bar graphs indicate mean ± SEM log2 counts per
million RNA-seq reads per population.Our previous work has shown that variants rs112233623 and
rs9349205 in CCND3 (Figure 5D), associated with MCV and
RBC count, act by modulating the expression levels of cyclin
D3, thereby affecting the number of cell divisions during terminal
erythropoiesis (Sankaran et al., 2012b; Ulirsch et al., 2019).
Although this had pronounced effects on the RBC count and
MCV (in opposite directions), HGB and HCT were less affected3234 Cell Reports 27, 3228–3240, June 11, 2019in Ccnd3-knockout mice, providing an example of how common
genetic variants modulate different erythroid traits at distinct
stages of erythropoiesis. Here, we show that both rs112233623
and rs9349205 fall within a single chromatin peak that opens up
in the BasoE, PolyE, and OrthoE stages (Figure 5D), consistent
with the expected differentiation stage of these variants’ pheno-
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Figure 6. Erythroid-Specific Isoform Expression and Regulation of TMCC2
(A) Line plot showing 14,640 differentially expressed genes across indicated populations, with TMCC2 highlighted.
(B) TMCC2 protein copy number across human erythroid populations.
(C) TMCC2 locus with corresponding RNA-seq (top) and ATAC-seq data (bottom) across indicated populations. Track plot depicting two isoforms of TMCC2 is
shown in the middle. Compared with MyP-PolyE stages, certain regions lose chromatin accessibility (blue shade), whereas others gain accessibility in late
erythropoiesis (OrthoE, pink shade). The shorter TMCC2 isoform is the dominant isoform expressed in blood cells.
(D) Schematic showing the KRAB domain fused to dCas9 used to target the enhancer (pink shade) or promoter (gray shade) non-coding DNA regulatory regions in
the TMCC2 locus. ATAC-seq tracks of HUDEP-2 cells of the TMCC2 locus are shown in green.
(E) Guide RNAs targeting the enhancer and promoter result in reduction of TMCC2 expression as determined using RT-qPCR in HUDEP-2 cells. Error bars
represent ± 1 SD between replicates.
(legend continued on next page)
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withmaximumchromatin accessibility at the later stages of eryth-
ropoiesis (BasoE to OrthoE) encompassing rs80326512 (Fig-
ure S5E), a fine-mapped (PP = 0.24) variant associated with
MCV. When considered together with the expression of KLF1
and its target gene set both peaking during terminal stages (Fig-
ures S4D and S4E), these findings suggest that rs80326512 acts
primarily during the late stages of erythropoiesis. As a third
example, a fine-mapped MCV variant, rs117747069 (PP = 1.00),
falls in a region that is both (1) maximally accessible during late
stages of erythropoiesis and (2) correlated with alpha-globin
expression (Figure S5F) (Iotchkova et al., 2016).
Going the other direction, genetic fine-mapping identified two
putative causal variants (rs28357093, PP = 0.33; rs833070, PP =
0.28) in the vascular endothelial growth factor A (VEGFA) locus
associated with HGB and HCT, both falling in regions with
higher chromatin accessibility at earlier stages of erythropoiesis
(CFU-E, ProE1/2) (Figure 5E). VEGFA has been shown to regu-
late erythropoietin signaling in response to hypoxia (Rehn
et al., 2014; Tam et al., 2006), suggesting that VEGFA may pref-
erentially act during early erythropoiesis to modulate expansion
of total erythroid cell mass. Other variants in early-accessible re-
gions included HGB-associated rs1175550 (PP = 0.36), a known
modifier of SMIM1 that encodes the Vel blood group antigen
(Ulirsch et al., 2016), and rs218264 (PP = 0.31) upstream of
KIT, an essential receptor tyrosine kinase for hematopoietic pro-
genitor cells (Figures S5G and S5H) (Edling and Hallberg, 2007).
Our integrative findings suggest that these variants and associ-
ated genes may play a more dominant role in the regulation of
HGB and HCT during early rather than late stages of erythroid
differentiation.
Finally, certain loci may contain multiple regulatory elements
active at distinct stages of erythropoiesis, as exemplified by
the HBS1L-MYB intergenic region. One HCT-associated (PP =
0.18) variant from our data, rs66650371, falls within a region
with maximal chromatin accessibility at the CFU-E, ProE1/2
stages (Figure 5F) and has been previously implicated as a func-
tional variant significantly associated with fetal HGB and MYB
expression (Stadhouders et al., 2014). In contrast, another fine-
mapped HBS1L-MYB intergenic variant associated with several
erythroid traits (HCT, PP = 0.27; HGB, PP = 0.15; RBC count,
PP = 0.10), rs9402685, falls within a region with increased chro-
matin accessibility in BasoE to OrthoE populations. Strikingly,
both rs66650371 and rs9402685 localize within functional
enhancer elements (84 and 83 kb upstream of theMYB tran-
scription start site) previously shown to block erythroid differen-
tiation and reduce MYB expression upon their deletion (Canver
et al., 2017). Although complex linkage disequilibrium (LD) struc-
ture prevents us from ruling out the possibility of other causal
variants in these two loci, the present analysis expands upon
our previous work (Guo et al., 2017) and adds insights into the
complex regulation at the HBS1L-MYB region by suggesting
that the84 element likely acts at early stages of erythropoiesis,(F and G) Bar plots showing RNA-seq expression counts per million (CPM) fo
guide RNAs (gRNAs) targeting the enhancer and a non-targeting guide. Erro
gRNAs.
(H) Volcano plot of all genes considered for differential expression between the p
3236 Cell Reports 27, 3228–3240, June 11, 2019whereas the 83 element may act at later stages of erythropoi-
esis. Altogether, our stage-specific matched profiles of ATAC-
seq and RNA-seq are beginning to provide a comprehensive
resource to delineate specific differentiation stages at which
various erythroid phenotypes and genes are most highly regu-
lated, allowing functional follow-up of nominated variants and
genes at high temporal and stage-specific resolution.
An Erythroid-Specific Isoform of TMCC2 Is an Essential
Regulator of Terminal Human Erythropoiesis
Our dataset provides a rich resource to expedite functional
studies of regulators of erythropoiesis. Highlighting one such
example, we identified TMCC2 as one of the most strongly
induced genes during the terminal stages of erythroid differenti-
ation (Figure 6A). TMCC2 is highly expressed in the human brain
and has been implicated in neurodegeneration (Hopkins, 2013),
but a role in hematopoietic development has not been previously
described (Figure S6A). Of note, TMCC2 showed high expres-
sion in whole blood, appeared to be selectively expressed in
erythroblasts (Figures S6A and S6B) with maximum protein
expression levels at the OrthoE stage (Figure 6B) (Gautier
et al., 2016), and was strongly induced in differentiating G1E-
ER cells, suggesting a cell type-specific role in erythropoiesis
(Figure S6C). Surprisingly, we observed decreasing chromatin
accessibility near the promoter of the reference transcript (Fig-
ure 6C, bottom, blue shade), but an increase in accessible chro-
matin at an alternative promoter and nearby putative enhancer in
late stages, supporting an isoform (ENST00000329800.7) of
TMCC2 that is blood specific (Figure S6D). Indeed, coverage
tracks of the RNA-seq data uniquely supported the expression
of the shorter isoform, indicating that this transcript may have
a specific role in erythropoiesis (Figure 6C, top). To confirm the
functional roles of these regulatory elements, we used a CRISPR
interference (CRISPRi) strategy, taking advantage of the local
heterochromatin formation and functional silencing mediated
by a Kruppel-associated box (KRAB) domain fused to a catalyt-
ically dead Cas9 (dCas9) (Figures 6D and S6E) (Gilbert et al.,
2014). Consistent with a role in TMCC2 gene regulation, we
observed significant downregulation of transcript levels as
measured by qRT-PCR upon targeting the promoter or enhancer
of TMCC2 with two independent guide RNAs in HUDEP-2 cells
(Kurita et al., 2013), which was more pronounced when targeting
the promoter (Figure 6E). Importantly, the enhancer showed
great specificity for TMCC2 regulation as determined using
RNA-seq analysis (Figures 6F–6H).
To interrogate a potential functional role and the relevance of
TMCC2 in RBC differentiation, we introduced two independent
short hairpin RNAs (shRNAs sh1 and sh2, both targeting the
30 end of the gene) by lentiviral infection to knockdown its expres-
sion using our primary erythroid culture system. Both shRNAs
resulted in pronounced reduction of TMCC2 mRNA levels
compared with a non-targeting control (shluc) as measured byr TMCC2 (F) and other expressed genes (G) in the locus when treated with
r bars represent ± 1 SD between replicates. (G) Pools replicates between































































Figure 7. TMCC2 Is an Essential Regulator of Terminal Human
Erythropoiesis
(A) Short hairpin RNAs (sh1 and sh2) knockdown TMCC2 expression as
determined using RT-qPCR in in vitro cultured primary hematopoietic cells.
Error bars represent ± 1 SD between replicates.
(B) Erythroid cells with shRNA knockdown of TMCC2 demonstrate reduced
proliferative capacity compared with a non-targeting control (shluc). Day
(x axis) represents the day following the start of the culture, representing days
3, 5, and 8 post-infection at the three indicated time points. Error bars repre-
sent ± 1 SD between replicates.
(C and D) TMCC2-knockdown cells further show increased frequency of
apoptotic annexin V+ cells (C) and impaired erythroid differentiation (D) as
shown by altered morphology and an increased frequency of disrupted cells
(arrows, 633 magnification, MayGrunwald staining). In (C), error bars repre-
sent ± 1 SD between replicates.qRT-PCR (Figure 7A). Knockdown of TMCC2 resulted in altered
cell proliferation (Figure 7B) and reduced levels of cellular viability
as indicated by flow cytometry with altered forward and side
scatter properties (Figure S7A). We also noted increased cell
apoptosis as measured by annexin V staining and use of DNA
binding dyes (Figures 7C, S7A, and S7B). We did not observe
significant alterations in the expression of erythroid markers
CD71 and CD235a in knockdown compared with control cells
(shluc) (Figure S7B). However, terminal erythroid maturation ap-
peared significantly impaired as demonstrated by altered cellular
morphology and an increased frequency of ‘‘disrupted’’ cells on
Cytospin images of TMCC2-knockdown cells (Figure 7D, arrows).
As such, the observed decrease in proliferation (Figure 7B) may
also be in part a consequence of increased cell lysis in these
late stages of erythroid differentiation. Finally, from population-based sequencing studies of healthy individuals (ExAC) (Lek
et al., 2016), we observed fewer than expected loss of function
(observed = 3, expected = 12) andmissense (observed = 216, ex-
pected = 330) variants in TMCC2, suggesting that mutations in
this gene are poorly tolerated and selected against (constraint
metric z = 3.07). Taken together, these results identify an
erythroid-specific isoform of TMCC2 as an essential regulator
of human terminal erythroid differentiation.
DISCUSSION
Here, we paired RNA-seq and ATAC-seq to provide deep tran-
scriptomic profiles and describe the dynamic accessible
chromatin landscape across distinct stages of adult human
erythroid differentiation. Our work provides a rich resource for
functional studies and complements previously published tran-
scriptomic and proteomic datasets (An et al., 2014; Gautier
et al., 2016; Li et al., 2014; Yan et al., 2018). Although prior
studies have performed epigenomic analyses at specific stages
(Buenrostro et al., 2018; Corces et al., 2016; Huang et al.,
2016), our comprehensive analysis across the entire process
of human erythroid differentiation provides substantial insights.
We comprehensively characterized differential regions of
accessible chromatin across erythroid development and identi-
fied regulatory elements with maximum accessibility specific to
PolyE and OrthoE, stages associated with nuclear condensa-
tion and overall decreasing accessibility (Figures 1E and 6).
Furthermore, we inferred the TF dynamics and their expression
programs that govern the molecular circuits of RBC differentia-
tion (Figures 3 and 4), inferred their maximum activity, and iden-
tified TF motifs most accessible in polychromatic and OrthoEs,
although their exact roles and transcriptional programs remain
to be functionally validated. Although the chromatin accessi-
bility profiles identified in this work enable robust inference of
accessibility peaks and global TF dynamics, these data have
limited capacity to identify site-specific TF binding (via TF-foot-
printing) or nucleosome positioning. Thus, additional assays
applied in our in vitro system, such as ChIP-seq of specific fac-
tors, may further reveal insights into dynamic chromatin states
during erythropoiesis.
Integration of ATAC-seq profiles with summary statistics from
GWAS and Mendelian erythroid disorders further enable the
nomination of genetic variants acting in gene regulatory ele-
ments and imply a potential window of activity (Figures 4
and 5). Our analyses suggest that regulatory elements and the
variants harbored within may showmaximum activity at different
stages of erythroid differentiation, thereby affecting distinct
erythroid traits or causing different blood disease phenotypes.
Variants in regulatory regions associated with HGB and HCT ap-
peared to be primarily accessible and regulate gene expression
at the early stages of RBC development. In contrast, RBC count
and MCV were primarily affected by regulatory elements con-
taining variants most accessible in late stage erythroblasts, as
showcased by our previous work characterizing the role of cyclin
D3 in terminal mouse and human erythropoiesis (Sankaran et al.,
2012b). We nominate multiple additional gene regulatory ele-
ments containing common variants associated with distinct
erythroid traits and suggest stage-specific activities, suggestingCell Reports 27, 3228–3240, June 11, 2019 3237
that our data may aid in the identification of non-coding variants
underlying GWAS results.
Because 90% of variants identified in GWAS (including he-
matopoietic traits) are in the non-coding genome (Ulirsch et al.,
2019), cell type-specific epigenomic profiling provides a powerful
means for more precise annotations of functionally relevant
variants underlying human phenotypes. As such, we anticipate
that our resource will inform functional validation studies, which
may further include the use of chromatin conformation capture,
massively parallel reporter assays, and genome editing ap-
proaches via CRISPR and related methods (Canver et al., 2017;
Ulirsch et al., 2016; Wakabayashi et al., 2016). As an example,
our data identified a blood-specific isoform of TMCC2 that is
highly induced at the PolyE/OrthoE stage (Figure 6). Knockdown
of TMCC2 resulted in pronounced proliferation and differentiation
defects, enabling us to identify this gene as an essential regulator
of terminal human erythropoiesis (Figure 7). In summary, our data
provide a comprehensive resource on the expression dynamics,
TF elements and their transcriptional programs, as well as their
relation to genetic variation to inform functional studies of human
erythroid differentiation.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human erythroid cell culture
Human adult CD34+ hematopoietic stem and progenitor cells were obtained from the Fred Hutchinson Hematopoietic Cell Process-
ing and Repository (Seattle, USA). No human subjects were involved in this study. The CD34+ samples were deidentified and
approval for use of these samples was provided by the Institutional Review Board and Biosafety Committees at Boston Children’s
Hospital. Donor characteristics: ID R003221 (Female, 65 years old), ID R003498 (Female, 46 years old), ID R003172 (Male, 54 years
old). These cells were differentiated into mature erythroid cells utilizing a three-phase culture protocol (Giani et al., 2016; Hu et al.,
2013). In phase 1 (day 0 – 7), cells were cultured at a density of 105 - 106 cells per milliliter (ml) in IMDM supplemented with 2% human
AB plasma, 3% human AB serum, 1% penicillin/streptomycin, 3 IU/ml heparin, 10 mg/ml insulin, 200 mg/ml holo-transferrin, 1 IU
erythropoietin (Epo), 10 ng/ml stem cell factor (SCF) and 1 ng/ml IL-3. In phase 2 (day 7 – 12), IL-3 was omitted from the medium.Cell Reports 27, 3228–3240.e1–e7, June 11, 2019 e3
In phase 3 (day 12 – 18), cells were cultured at a density of 106 cells per milliliter, with both IL-3 and SCF omitted from themedium and
the holo-transferrin concentration was increased to 1 mg/ml. Cells were cultured at 37C and 5% CO2.
HUDEP-2 cell culture
HUDEP-2 cells were maintained in StemSpan SFEM II medium (Stem Cell Technologies) supplemented with hSCF (50 ng/ml),
erythropoietin (3 IU/ml), dexamethasone (106 M) and doxycycline (1 mg/ml). For erythroid differentiation cells were cultured in
differentiation media (IMDM, 2% human AB plasma, 3% human AB serum, 1 mg/mL Holo-human transferrin, 3 IU/mL
heparin,10 mg/mL insulin and 3 IU/mL erythropoietin. Cells were cultured at 37C and 5% CO2.
293T cell culture
293T cells (ATCC) were maintained in DMEM (GIBCO) supplemented with 10% FBS, 1% penicillin/streptomycin and 2 mM L-gluta-
mine. Cells were cultured at 37C and 5% CO2.
METHOD DETAILS
Flow cytometry analysis and apoptosis
For flow cytometry analysis, in vitro cultured erythroid cells were washed in FACS buffer (1% FBS in PBS) before antibody staining.
The following antibodies at indicated dilutions were used in this study: 1:50 APC-conjugated CD235a (Glycophorin A, clone HIR2,
50-153-69, eBioscience), 1:50 FITC-conjugated CD71 (OKT9, 14-0719-82, eBioscience), 1:50 APC-conjugated CD49d (9F10,
Biolegend, 304308) and 1:200 FITC-conjugated BAND3 (An et al., 2014; Hu et al., 2013). For live/ dead cell discrimination Sytox
Blue was used according to the manufacturer’s instructions (Thermo Fisher, S34857). For apoptosis analysis, BV421-Annexin V
(BD Bioscience, 563973) was used in combination with Sytox Orange according to the manufacturer’s instructions (Thermo Fisher,
S34861). FACS analysis was conducted on aBDBioscience Fortessa flow cytometer at theWhitehead Institute FlowCytometry core.
Data were analyzed using FlowJo software v10.4.2.
Flow cytometry activated cell sorting
In vitro cultured erythroid cells were washed in FACS buffer and stained as described above using antibodies against CD235a, CD71,
CD49d and BAND3. Sytox Blue (Thermo Fisher, S34857) was used for live/ dead cell discrimination. Cells were sorted using a Sony
SH800 sorter with a 100 mm chip at the Broad Institute Flow Cytometry facility.
May-Gr€unwald-Giemsa staining
50,000 – 100,000 cells were harvested, washed once at 300 x g for 5min, resuspended in 200 mL of FACSBuffer, and spun onto poly-
L-lysine coated microscope slides with a Shandon 4 (Thermo Scientific) cytocentrifuge at 300 rpm for 4 min. When visibly dry slides
were transferred into May-Gr€unwald solution (Sigma-Aldrich) for 5 min, rinsed 4 times for 30 s in water, and transferred to Giemsa
solution (Sigma-Aldrich) for 15 min. Slides were washed as described above, dry mounted with coverslips, and examined. All images
shown were taken using a Metafer slide scanning platform and software (Metasystems) at 63X magnification.
FAST-ATAC-seq
For ATAC-seq library preparations 10,000-15,000 cells were washed in PBS, pelleted by centrifugation and lysed and tagmented in
1x TD buffer, 2.5 ml Tn5 (Illumina), 0.01%Digitonin (Promega, G9441), 0.3x PBS in a 50 ml reaction volume as described (Corces et al.,
2016). Samples were incubated at 37C for 30 min at 300 rpm. Tagmented DNA was purified using the MinElute PCR kit (QIAGEN).
The complete eluate underwent PCR, as follows. After initial extension, 5 cycles of pre-amplification using indexed primers (Buen-
rostro et al., 2015) and NEBNext High-Fidelity 2X PCRMasterMix (NEB) were conducted, before the number of additional cycles was
assessed by quantitative PCR using SYBR Green. Typically, 7-9 additional cycles were run. The final library was purified using a
MinElute PCR kit (QIAGEN) and quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a High Sensitivity DNA chip run on
a Bioanalyzer 2100 system (Agilent).
RNA-seq
Cells were lysed in RLT lysis buffer (QIAGEN) supplemented with beta-mercaptoethanol and RNA was isolated using a RNeasy
Micro kit (QIAGEN) according to the manufacturer’s instructions. An on-column DNase digestion was performed before RNA was
quantified using a Qubit RNA HS Assay kit (Invitrogen). 1-10 ng of RNA were used as input to a modified SMART-seq2 (Picelli
et al., 2014) protocol and after reverse transcription, 8-9 cycles of PCR were used to amplify transcriptome library. Quality of whole
transcriptome libraries was validated using aHigh Sensitivity DNAChip run on aBioanalyzer 2100 system (Agilent), followed by library
preparation using the Nextera XT kit (Illumina) and custom index primers according to the manufacturer’s instructions. Final libraries
were quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a High Sensitivity DNA chip run on a Bioanalyzer 2100 system
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Sequencing
All libraries were sequenced usingNextseq HighOutput Cartridge kits and aNextseq 500 sequencer (Illumina). Libraries were consis-
tently sequenced paired end (2x38bp).
Western blotting
Cells were washed twice in PBS, resuspended in RIPA lysis buffer (Santa Cruz Biotechnology) supplemented with 1x Complete
Protease Inhibitor Cocktail (Roche) and incubated for 30 min on ice. After centrifugation at 14,000 rpm for 10 min at 4C to remove
cellular debris, the remaining supernatant was transferred to a new tube, supplemented with 4x Laemmli sample buffer (Bio-Rad) and
beta-mercaptoethanol and incubated for 10 min at 95C. Equal amounts of proteins were separated by gel electrophoresis using the
Mini-PROTEAN gel system and Tris/Glycine/SDS running buffer (Bio-Rad). Subsequently, proteins were transferred onto a PVDF
membrane using Tris/Glycine transfer buffer supplemented with methanol (Bio-Rad). Membranes were blocked with 3% BSA-
TBST for 1 h and probed with GATA1 goat polyclonal antibody (M-20, sc-1234, Santa Cruz Biotechnology) at a 1:500 dilution or
b-actin mouse monoclonal (AC-15, Sigma) at a 1:5,000 dilution in 3% BSA-TBST for 1 h at room temperature or overnight at 4C.
Membranes were washed four times with TBST, incubated with donkey anti-mouse or anti-goat peroxidase-coupled secondary
antibodies (715-035-150 and 705-035-147, Jackson ImmunoResearch) at a 1:10,000 dilution in 3% BSA-TBST for 1 h at room
temperature, washed three times with TBST and incubated for 1 min with Western Lightning Plus-ECL substrate (PerkinElmer).
Proteins were visualized by exposure to scientific imaging film (Kodak).
Lentiviral shRNA vectors and infection
The shRNA constructs targeting human TMCC2 (sh1 and sh2, SHCLNG-NM_014858) were obtained from theMission shRNA collec-
tion (Sigma-Aldrich). The sequences of the shRNAs used in this study are
sh1: CCGGGCAAGTGTTCGAGAAGAAGAACTCGAGTTCTTCTTCTCGAACACTTGCTTTTTTG
sh2: CCGGCCTGACTGAGCTTCATCAGAACTCGAGTTCTGATGAAGCTCAGTCAGGTTTTTTG
As controls, the lentiviral vectors pLKO-GFP and shluc were used. For production of lentiviruses, 293T cells were transfected with
the appropriate viral packaging and genomic vectors (pVSV-G and pDelta8.9) using FuGene 6 reagent (Promega) according to the
manufacturer’s protocol. The medium was changed the day after transfection to phase I medium (described above). After 24-30 h,
this medium was collected and filtered using an 0.22 mm filter immediately before infection of primary hematopoietic cells. The cells
were mixed with viral supernatant supplemented with cytokines in the presence of 8 mg/ml polybrene (Millipore) in a 6-well plate at a
density of 250,000–500,000 cells per well. The cells were spun at 2,000 rpm. for 90 min at 22C and left in viral supernatant overnight.
The medium was replaced the morning after infection. Selection of infected cells was started 24 h after infection with 1 mg/ml puro-
mycin for up to 48 h. Infection efficiency of pLKO-GFP–infected cells was assessed bymeasuring the frequency of GFP+ cells by flow
cytometry 48-72 h post infection. Typically, the frequency of GFP+ cells was between 40%–70%.
Construction of the lentiviral CRISPRi constructs
We utilized the LentiCRISPRv2 backbone for constructing the CRISPRi constructs (Sanjana et al., 2014). The sgRNA scaffold in this
construct was replaced by sgRNA-(F+E)-combined optimized scaffold from the sgOpti plasmid (Addgene # 85681) (Fulco et al.,
2016). The puromycin resistance gene was replaced with the GFP gene using BamHI and SacII sites. To achieve better expression
in hematopoietic cells, the EF1a promoter was replaced by the MSCV promoter using Gibson assembly. The SpCas9 was replaced
with the KRAB-dCas9 from the pHR-SFFV-KRAB-dCas9-P2A-mCherry construct using BamHI sites (Addgene: #60954) (Gilbert
et al., 2014). A scheme of the vector construct is shown in Figure S6E. The sequences of the guide RNAs used in this study are:
Control / non-targeting guide: ATCGCGAGGACCCGTTCCGCC
TMCC2 promoter gRNA1: CCTGGCAAAGCATATTACAT
TMCC2 promoter gRNA2: GTATAGTTTCCATGAGCCCA
TMCC2 enhancer gRNA1: GTCGTGCTGCAGGTGAAGTG
TMCC2 enhancer gRNA2: CCATCCTTCAGAGTAAACAG
CRISPRi experiments in HUDEP-2 cells
The cells were infected with all-in-one CRISPRi lentviral constructs containing KRABdcas9 driven by the MSCV promoter linked to
GFP (by a self-cleaving 2A peptide sequence from porcine teschovirus) and an U6 promoter driving respective guide RNAs targeting
the TMCC2 gene locus. HUDEP-2 cells were infected as described above and GFP+ cells were FACS sorted 48 h post-infection and
expanded for an additional 6 days. HUDEP-2 cells were then differentiated in erythroid differentiation media as described above for
72 h and RNA was extracted using a RNeasy Mini kit (QIAGEN) for gene expression analysis. RNA-seq libraries were constructed for
three replicates of the non-targeting gRNA and two replicates for each of the on-target enhancer gRNAs. Differential gene expression
analysis was performed as stated below for the FACS-sorted primary cells.Cell Reports 27, 3228–3240.e1–e7, June 11, 2019 e5
Quantitative RT-PCR
Isolation of RNA was performed using the RNeasy Mini Kit (QIAGEN). An on-column DNase (QIAGEN) digestion was performed
according to the manufacturer’s instructions. RNA was quantified by a NanoDrop spectrophotometer (Thermo Scientific). Reverse
transcription was carried out using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using the CFX384 Real-
Time PCR system and iQ SYBR Green Supermix (Bio-Rad). Quantification was performed using the DDCT method. Normalization





TMCC2 forward 2: 50-CTACATGACCCAGTGCCTGC-30
TMCC2 reverse 2: 50-CTCCTGCTTCAGGTTCGTCA-30
QUANTIFICATION AND STATISTICAL ANALYSIS
Data processing and read alignment
For each sequencing library generated in this study, libraries were sequenced on an Illumina NextSeq 500 and demultiplexed using
the bcl2fastq program. For each library, raw .fastq reads were aligned using either Bowtie2 version 2.3.3 (ATAC-seq) (Langmead and
Salzberg, 2012) or STAR version 2.5.1b (RNA-seq) (Dobin et al., 2013) to the hg19 reference genome. Chromatin accessibility peaks
were called using MACS2 using custom parameters for ATAC-seq (–nomodel–nolambda–keep-dup all–call-summits) (Zhang et al.,
2008). Gene expression counts were summarized using the–quantMode functionality in STAR. Downstream processing of
sequencing data was performed using Samtools (Li et al., 2009). Per population ATAC and RNA-seq values were visualized as heat-
maps were generated using Complexheatmap (Gu et al., 2016).
Principal component analyses
To establish a uniform feature set for the ATAC-seq data, we used all 1 bp summits from the MACS2 peak calls per population and
expanded them a uniform 250 bp, similar to a strategy implemented previously (Corces et al., 2016). Summits overlapping the same
windowwere iteratively centered at the summit with the strongest signal (measured by -log10 FDR) until all summits were accounted.
Gene x sample and Peak x sample matrices were log2 counts-per-million normalized and then transformed to Z scores before the
first two principle components were computed via the implicitly restarted Lanczos bidiagonalization algorithm (irlba).
Differential gene expression and chromatin occupancy
To test for differential gene expression from our RNA-seq data and differential chromatin accessibility in individual loci, we used the
DEseq2 method (Love et al., 2014). Statistically significant genes varying between two populations were identified at an independent
hypothesis weighting (IHW) value of 0.01 (Ignatiadis et al., 2016). A total of 56 comparisons between populations were performed
(28 for ATAC-seq; 28 for RNA-seq).
Gene set enrichments
Gene set enrichments of 7 clusters of differentially expressed genes were performed using the Functional Mapping and Annotation of
Genome-Wide Associations (FUMA) platform, using all protein-coding genes as backgroundmodel and requiring aminimum overlap
of 2 genes and an FDR-adjusted p < 0.01 for each gene-set. Only Gene Ontology (GO) biological processes were considered.
Downstream ATAC-seq analyses
All motif analyses were performed using the motifmatchr package as part of the chromVAR suite of tools (Schep et al., 2017). For
insertion footprinting analyses, reads were offset by +4/-5 base pairs as originally described (Buenrostro et al., 2013). Transcription
factor activity scoringwas performed using combined replicates for each population for both the data generated in this study (Figures
3C and 3D) and augmented with populations previously described (Corces et al., 2016) (Figures S3C and S3D). We note that as
chromVAR builds a background peak set based on the population intensities, deviation z-scores are not absolute but relative to
the populations considered.
Integration with Genome-Wide Association Studies
We obtained GWAS summary statistics and fine-mapping results of 6 erythroid traits (HGB, HCT, MCV, RBC count, MCH, and
MCHC), which were performed on 115,000 individuals of European ancestry from the UK Biobank, as described extensively else-
where (Ulirsch et al., 2019). For g-chromVAR enrichment analysis, the set of all fine-mapped variants with PP > 0.001 for each trait
were used as input.
Next, to nominate high-confidence fine-mapped variants located in strong chromatin peaks, we took the consensus peak set for all
stages of erythropoiesis, performed row and column quantile normalization on the counts matrix, and kept only peaks that had ae6 Cell Reports 27, 3228–3240.e1–e7, June 11, 2019
maximum count in the top 80% for at least one of the eight sampled cell populations. We then overlapped fine-mapped variants with
posterior probability (PP) > 0.10 with this subset of strong peaks.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw sequencing data reported in this paper is GEO: GSE115684 and is available at https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE115684. AUCSCTrackHub for the ATAC-seq data generated for these eight populations is
available here: https://s3.amazonaws.com/atacerythropoiesis/hub.txt. A git repository containing code for analyses described here
and processed data files is available at www.github.com/sankranlab/erythroid-profiling.Cell Reports 27, 3228–3240.e1–e7, June 11, 2019 e7
